search
Back to results

Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind) (AGES-Mind)

Primary Purpose

Schizophrenia and Disorders With Psychotic Features, Psychotic Episode

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
SocialMIND
Psychoeducational multicomponent intervention
Psychosocial treatment
Psychotropic treatment
Sponsored by
Instituto de Investigación Hospital Universitario La Paz
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Schizophrenia and Disorders With Psychotic Features focused on measuring first episode psychosis, early psychosis, schizophrenia, mindfulness, social cognition, social functioning, AGES-Mind, SocialMind

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18-45 years old
  • First hospitalization, first visit to mental health services with positive symptoms, onset of antipsychotic treatment, or first appearance of positive symptoms confirmed by an informant within the period of five years prior to the enrolment in the study;
  • Informed consent given

Exclusion Criteria:

  • Clinical Global Impression (CGI) higher than 5 ("markedly ill")
  • Other Axis I diagnoses, except for substance use if psychotic symptoms remain at least 14 days after negative urine test.
  • Intellectual disability plus impaired global functioning prior to disorder onset
  • Generalized development disorder
  • Pregnancy
  • Attendance to either mindfulness programs or structured psychoeducational interventions at the time of the enrolment

Sites / Locations

  • La Paz University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

SocialMIND

Psychoeducational Multicomponent Intervention

Arm Description

The experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.

The active comparator arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and a psychoeducational multicomponent intervention for psychosis.There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 7 monthly sessions.

Outcomes

Primary Outcome Measures

Change in social functioning
Personal and Social Performance Scale (PSP) measures patient's functioning on different social areas, such as self-care, relationships, social activities and aggressive behavior.

Secondary Outcome Measures

Change in global functioning
Global Assessment of Functioning Scale (GAF) measures patient's general functioning using a single 0-100 scale.
Change in quality of life
WHOQOL-BREF measures patient's quality of life according to World Health Organization parameters.
Change in clinical global impression
Clinical Global Impression Scale for Schizophrenia (CGI-SCH) measures patients' clinical state and clinical change over time
Change in psychotic symptoms
Positive and Negative Symptoms Scale for Schizophrenia (PANSS) measures psychotic syndrome through a detailed clinical interview.
Change in depressive symptoms
Calgary Depression Scale for Schizophrenia (CDSS) measures depressive symptoms in psychotic patients through a personal interview
Change in anxiety symptoms
Beck Anxiety Inventory (BAI) measures clinical anxiety through 21 items.
Change in social cognition
Hinting task, Reading the Mind in the Eyes Test (RMET), Emotion Recognition task (ER-40) and Ambiguous Intentions and Attribution Questionnaire (AIHQ) measure main domains of social cognition.
Change in reflective functioning
Reflective Functioning Questionnaire (RFQ-8) measures mentalization ability through a set of 8 questions
Change in emotional intelligence
Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT v2.0) measures emotional intelligence through a set of questions referred to different situations.
Change in mindful attention and awareness
Mindfulness Attention Awareness Scale (MAAS) measures processes thought to be related to clinical outcomes in mindfulness-based interventions.
Change in cognitive insight
Beck Cognitive Insight Scale (BCIS) explores self-reflection and self-certainty, as parts of the cognitive insight construct
Change in neurocognition
Four tasks of the Matrics Consensus Cognitive Battery (MCCB) measure different domains of neurocognition (symbol coding, letter number span, spatial span and CPT-IP)
Change in oxidative stress and anti-inflammatory response
Total antioxidant status, enzymatic activity and cytokines

Full Information

First Posted
September 27, 2017
Last Updated
August 2, 2022
Sponsor
Instituto de Investigación Hospital Universitario La Paz
Collaborators
Carlos III Health Institute, European Regional Development Fund
search

1. Study Identification

Unique Protocol Identification Number
NCT03309475
Brief Title
Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind)
Acronym
AGES-Mind
Official Title
Mindfulness-based Social Cognition Group Training (SocialMIND) Versus Psychoeducational Multicomponent Intervention in Patients With a First Episode of Psychosis (AGES-Mind Study): A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2018 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Instituto de Investigación Hospital Universitario La Paz
Collaborators
Carlos III Health Institute, European Regional Development Fund

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The current investigation aims to compare two group intervention in patients with a first episode of psychosis, that is, people who have suffered their first psychotic episode within 5 years prior to their inclusion in the study. The experimental arm is a mindfulness-based social cognition training (SocialMind) designed by professionals with both formal training and clinical experience in the field of mindfulness and third generation cognitive-behavioral therapies. The active comparator arm is a psychoeducation program specifically designed for individuals with recent onset psychosis by members of the team with great experience in delivering such interventions. The main outcome is social functioning, as measured by the Personal and Social Performance Scale (PSP), an instrument developed for psychotic patients. The main hypothesis is that the improvement in social functioning will be larger among the participants on the experimental arm, because there is enough evidence suggesting that deficits in social cognition are present even in the first stages of psychotic syndrome and related to social functioning and general disability. Moreover, mindfulness-based interventions have proven themselves effective in other severe mental disorders.
Detailed Description
Social functioning is impaired among many patients with a first episode of psychosis, who also show a lower ability to recognize, understand and benefit from social stimuli (i.e., deficits in social cognition) than their pairs. Both deficits underlie the general functional impairment found across non-affective psychotic syndromes. Since currently available pharmacological strategies have not proven themselves effective in addressing this matter, new psychotherapeutic approaches should be developed. Investigators' main hypothesis is that a mindfulness-based social cognition group training (SocialMind) will improve social and general functioning, and that this improvement will be higher in the SocialMind than in the psychoeducation group. Given the association between oxidative stress and cognitive functioning, a relationship between oxidative stress biomarkers and intervention-related variables is also expected. A research team with more than ten mental health professionals and many collaborators will carry and oversee the assessment sessions. A Pharmacology Department will analyse the biological samples. Regulated-trained, well-experienced clinicians will design and administer both interventions. The whole team will take part in the process of scientific publication and results dissemination.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia and Disorders With Psychotic Features, Psychotic Episode
Keywords
first episode psychosis, early psychosis, schizophrenia, mindfulness, social cognition, social functioning, AGES-Mind, SocialMind

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Pilot, multi-center, rater-blinded, prospective (48-weeks follow-up), randomized, controlled (versus active comparator [psychoeducation]), clinical trial. The experimental arm will receive treatment as usual (both drug and psychosocial therapy) and mindfulness-based social cognition group training, specifically designed for patients with first episode psychosis by the research team. The active comparator arm will receive treatment as usual (both drug and psychosocial therapy) and psychoeducation group training for psychosis.
Masking
InvestigatorOutcomes Assessor
Masking Description
The evaluators will not know the patients' assigned treatment arm until the end of the follow-up period. This information will only be delivered to investigators in charge of intervention groups, but not to those in charge of statistical analyses.
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SocialMIND
Arm Type
Experimental
Arm Description
The experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
Arm Title
Psychoeducational Multicomponent Intervention
Arm Type
Active Comparator
Arm Description
The active comparator arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and a psychoeducational multicomponent intervention for psychosis.There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 7 monthly sessions.
Intervention Type
Behavioral
Intervention Name(s)
SocialMIND
Other Intervention Name(s)
Mindfulness-based social cognition training, Mindfulness-based social cognition group training, MB-SCT
Intervention Description
SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.
Intervention Type
Behavioral
Intervention Name(s)
Psychoeducational multicomponent intervention
Other Intervention Name(s)
PMI, Structured psychoeducational group, Psychoeducational group, Psychoeducation group
Intervention Description
The psychoeducational multicomponent intervention addresses and discuss several aspects of great importance for persons who suffer a first episode of psychosis, such as biased perception and thinking, delusions-related anxiety or the nature of hallucinations. Its aim is to encourage patients to reflect upon their experiences from a critic perspective.
Intervention Type
Behavioral
Intervention Name(s)
Psychosocial treatment
Intervention Description
Treatment as usual delivered by patient's practitioner
Intervention Type
Drug
Intervention Name(s)
Psychotropic treatment
Other Intervention Name(s)
Drug treatment
Intervention Description
Treatment as usual delivered by patient's practitioner
Primary Outcome Measure Information:
Title
Change in social functioning
Description
Personal and Social Performance Scale (PSP) measures patient's functioning on different social areas, such as self-care, relationships, social activities and aggressive behavior.
Time Frame
8, 16, 36 and 48 weeks
Secondary Outcome Measure Information:
Title
Change in global functioning
Description
Global Assessment of Functioning Scale (GAF) measures patient's general functioning using a single 0-100 scale.
Time Frame
8, 16, 36 and 48 weeks
Title
Change in quality of life
Description
WHOQOL-BREF measures patient's quality of life according to World Health Organization parameters.
Time Frame
8, 16, 36 and 48 weeks
Title
Change in clinical global impression
Description
Clinical Global Impression Scale for Schizophrenia (CGI-SCH) measures patients' clinical state and clinical change over time
Time Frame
8, 16, 36 and 48 weeks
Title
Change in psychotic symptoms
Description
Positive and Negative Symptoms Scale for Schizophrenia (PANSS) measures psychotic syndrome through a detailed clinical interview.
Time Frame
8, 16, 36 and 48 weeks
Title
Change in depressive symptoms
Description
Calgary Depression Scale for Schizophrenia (CDSS) measures depressive symptoms in psychotic patients through a personal interview
Time Frame
8, 16, 36 and 48 weeks
Title
Change in anxiety symptoms
Description
Beck Anxiety Inventory (BAI) measures clinical anxiety through 21 items.
Time Frame
8, 16, 36 and 48 weeks
Title
Change in social cognition
Description
Hinting task, Reading the Mind in the Eyes Test (RMET), Emotion Recognition task (ER-40) and Ambiguous Intentions and Attribution Questionnaire (AIHQ) measure main domains of social cognition.
Time Frame
8, 16, 36 and 48 weeks
Title
Change in reflective functioning
Description
Reflective Functioning Questionnaire (RFQ-8) measures mentalization ability through a set of 8 questions
Time Frame
8, 16, 36 and 48 weeks
Title
Change in emotional intelligence
Description
Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT v2.0) measures emotional intelligence through a set of questions referred to different situations.
Time Frame
8, 16, 36 and 48 weeks
Title
Change in mindful attention and awareness
Description
Mindfulness Attention Awareness Scale (MAAS) measures processes thought to be related to clinical outcomes in mindfulness-based interventions.
Time Frame
8, 16, 36 and 48 weeks
Title
Change in cognitive insight
Description
Beck Cognitive Insight Scale (BCIS) explores self-reflection and self-certainty, as parts of the cognitive insight construct
Time Frame
8, 16, 36 and 48 weeks
Title
Change in neurocognition
Description
Four tasks of the Matrics Consensus Cognitive Battery (MCCB) measure different domains of neurocognition (symbol coding, letter number span, spatial span and CPT-IP)
Time Frame
8, 16, 36 and 48 weeks
Title
Change in oxidative stress and anti-inflammatory response
Description
Total antioxidant status, enzymatic activity and cytokines
Time Frame
8 and 48 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18-45 years old First hospitalization, first visit to mental health services with positive symptoms, onset of antipsychotic treatment, or first appearance of positive symptoms confirmed by an informant within the period of five years prior to the enrolment in the study; Informed consent given Exclusion Criteria: Clinical Global Impression (CGI) higher than 5 ("markedly ill") Other Axis I diagnoses, except for substance use if psychotic symptoms remain at least 14 days after negative urine test. Intellectual disability plus impaired global functioning prior to disorder onset Generalized development disorder Pregnancy Attendance to either mindfulness programs or structured psychoeducational interventions at the time of the enrolment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Maria Fe Bravo, MD, PhD
Phone
(+34) 91 727 75 49
Email
mfe.bravo@salud.madrid.org
First Name & Middle Initial & Last Name or Official Title & Degree
Ainoa Munoz, MD, PhD
Phone
(+34) 91 727 75 49
Email
ainoa.munoz@idipaz.es
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maria Fe Bravo, MD, PhD
Organizational Affiliation
Instituto para la Investigación Biomédica del Hospital universitario La Paz (IdiPAZ)
Official's Role
Principal Investigator
Facility Information:
Facility Name
La Paz University Hospital
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ainoa Munoz, MD, PhD
Phone
+34917277549
Email
ainoa.munoz@salud.madrid.org
First Name & Middle Initial & Last Name & Degree
Roberto Mediavilla, MsC
Phone
+34917277276
Email
roberto.mediavilla@idipaz.es

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participant data will be available on request.
IPD Sharing Time Frame
The data will be available after the final results are published and for ever
IPD Sharing Access Criteria
Researchers that are interested should contact the Principal Investigator
Citations:
PubMed Identifier
25759473
Citation
Fond G, d'Albis MA, Jamain S, Tamouza R, Arango C, Fleischhacker WW, Glenthoj B, Leweke M, Lewis S, McGuire P, Meyer-Lindenberg A, Sommer IE, Winter-van Rossum I, Kapur S, Kahn RS, Rujescu D, Leboyer M. The promise of biological markers for treatment response in first-episode psychosis: a systematic review. Schizophr Bull. 2015 May;41(3):559-73. doi: 10.1093/schbul/sbv002. Epub 2015 Mar 10.
Results Reference
background
PubMed Identifier
15888423
Citation
Brune M. "Theory of mind" in schizophrenia: a review of the literature. Schizophr Bull. 2005 Jan;31(1):21-42. doi: 10.1093/schbul/sbi002. Epub 2005 Feb 16.
Results Reference
background
PubMed Identifier
24613006
Citation
Lecomte T, Corbiere M, Ehmann T, Addington J, Abdel-Baki A, Macewan B. Development and preliminary validation of the First Episode Social Functioning Scale for early psychosis. Psychiatry Res. 2014 May 30;216(3):412-7. doi: 10.1016/j.psychres.2014.01.044. Epub 2014 Feb 5.
Results Reference
background
PubMed Identifier
31357965
Citation
Mediavilla R, Munoz-Sanjose A, Rodriguez-Vega B, Bayon C, Palao A, Lahera G, Sanchez-Castro P, Roman E, Cebolla S, de Diego A, Pastor JM, Bravo-Ortiz MF. Mindfulness-based social cognition training (SocialMIND) versus psychoeducational multicomponent intervention for people with a first episode of psychosis: a study protocol for a randomised controlled trial. BMC Psychiatry. 2019 Jul 29;19(1):233. doi: 10.1186/s12888-019-2206-4.
Results Reference
derived
Links:
URL
http://www.idipaz.es/PaginaDinamica.aspx?IdPag=40&Lang=ES
Description
Research team in IdiPAZ
URL
http://www.madrid.org/cs/Satellite?language=es&pagename=HospitalLaPaz/Page/HPAZ_home
Description
La Paz University Hospital
URL
http://www.agescm.es/index.php?lang=es
Description
AGES-CM Consortium

Learn more about this trial

Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind)

We'll reach out to this number within 24 hrs